Rhythm Biosciences (ASX:RHY) secures a reinstatement of its National Association of Testing Authorities accreditation for the geneType cancer risk assessment assay portfolio, according to a Tuesday filing with the Australian bourse.
This follows the temporary suspension of the accreditation after the company acquired the geneType assets from Genetic Technologies (ASX:GTG), the filing said.
The reinstatement marks the conclusion of the integration of the geneType laboratory under the company's ownership, per the filing.
Shares were down 3% in afternoon trade on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。